Screening for high uric acid in fatty liver disease
Part of Digestive system, Hormones & metabolism, Kidney & urinary clinical trials.
This study is looking at whether people with fatty liver disease (MAFLD) also have high levels of uric acid in their blood, which is called hyperuricemia. It aims to find out how common this condition is and may help improve health care for people with fatty liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with fatty liver disease (MAFLD) using an imaging test like an ultrasound.
- You cannot be pregnant.
- You cannot have any current or past cancer.
- You cannot have type 1 diabetes.
- You cannot have had weight-loss (bariatric) surgery before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether higher uric acid levels in the blood are linked to liver scarring (fibrosis) in people with obesity. If you qualify, you may help doctors understand how to detect liver problems earlier.
This study checks if a common stomach bacteria (H. pylori) is linked to fatty liver disease. It may help doctors understand more about fatty liver and could lead to better treatments.
This study looks at people who are metabolically healthy but overweight or obese, and how that affects their risk of developing fatty liver disease (MASLD) or high uric acid levels (hyperuricemia). It aims to see if 'healthy' obesity still carries hidden health risks.
This study tests whether a simple blood test can help detect fatty liver disease in people who have metabolic syndrome. It may offer a less invasive way to identify liver problems early.
This study looks at how common obesity is in people with fatty liver disease (a condition where fat builds up in the liver). It aims to understand the relationship between these two conditions better, which might lead to improved care and prevention.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
Hear when a new Hyperuricemia and MAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.